Contents lists available at ScienceDirect Transfusion and Apheresis Science journal homepage: www.elsevier.com/locate/transci JACIE: A 20 year-old voluntary body functioning worldwide Meltem Kurt Yüksel ⁎ , Osman İlhan Ankara University, School of Medicine Hematology, Department and Bone Marrow Transplantation Unit, Turkey ARTICLE INFO Keywords: JACIE–accreditation-hematopoietic stem cell transplantation ABSTRACT Hematopoietic Stem Cell Transplantation (HSCT) is a well estabished treatment modality for patients with severe disorders of the hematopoietic system. HSCT is the pioneer of not the adoptive immunotherapy but also cellular therapies. It was first performed in 1957; since then the transplantation numbers have increased every year in almost all parts of the World. However, the increase in the quality of this procedure was not as fast as the numbers. The first Standards for hematopoeietic cell collection, processing and transplantation in Europe was established in 1998 by the European Group for Bone Marrow Transplantation (EBMT) and The International Society for Hematotherapy and Graft Engineering Europe I (SHAGE Europe) and the Joint Accreditation Committee of ISCT EBMT (JACIE) was founded. JACIE is a non-profit voluntary organization that helps all the stakeholders of HSCT, the teams, goverments, regulators, payers and, mostly, the patients. In this review the aims and the twenty years history of JACIE in the World and in Turkey is explained. 1. Introduction The annual numbers of hematopoietic stem cell transplantation (HSCT) in Europe increased from 18 in 1974, when the European Group for Blood and Marrow Transplantation (EBMT) was founded, to 4234 HSCT in 1990, when the EBMT activity survey was introduced, and to an estimated number of more than 20 000 patients in the year 2000 [1], and currently to more than 40 000 patients in the year 2016 [2]. Suc- cessful treatment of many patients with various diseases forms the basis of the continuing ambition and enthusiasm of the transplant commu- nity. Besides, voluntary accreditation of cellular therapies plays an important role in improving the quality of patient care and laboratory performance. It is based upon standards developed by consensus of professionals in the field: Foundation for Accreditation of Cellular Therapy (FACT) in US and Joint Accreditation Committe of Interna- tional Society of Cellular Therapy and European Group for Bone Marrow Transplantation (JACIE) in Europe. 1.1. History Hematopoietic Stem Cell Transplantation (HSCT) is an established therapy modality for the patients with severe disorders of the hema- topoietic system. The first allogeneic transplantation was performed by E. Donnall Thomas in 1957 [3]. Since then the field has evolved and expanded worldwide. Another breakthrough took place with the first transplantation which has been performed from an HLA-matched un- related donor (MUD). Hematopoietic stem cell transplantation from unrelated donors dramatically increased the odds for finding a match; for example, from 25% to 75% for Caucasian patients [4]. The first transplantations included acute leukemia and aplastic anemia however new indications have been constantly explored and now include con- genital disorders of the hematopoietic system, metabolic disorders, and autoimmune disease [3,4]. The use of matched unrelated donors, um- bilical cord blood units, and partially matched related donors has ex- tended the availability of allogeneic transplantation. The hematopoietic stem cells has been transported not only between cities but also be- tween countries. International collaboration was mandatory for the establishment of transplantation centers around the world and for a global donor and recipient registry. The International Bone Marrow Transplant Registry (IBMTR) and the European Group for Blood and Marrow Transplantation (EBMT) were established in 1972 and in 1974 respectively [5,6]. The goal was collaboration in the field of HSCT for documenting HSCT outcome data. The first unrelated donor trans- plantation inspired in 1986 the foundation of the National Marrow Donor Program (NMDP), and in 1988 Bone Marrow Donors Worldwide (BMDW) was founded [5,6]. At this time the issue was to prevent dif- ficulties in importing and exporting tissues across international boundaries, which could occur if there were to be differences in the standards adopted in different countries. In 1994, the Regulatory Af- fairs Committee of ISCT developed the first draft of Standards for He- matopoietic Cell Collection and Processing; and a subcommittee of the Clinical Affairs Committee of ASBMT drafted the Clinical Standards for Hematopoietic Cell Transplantation. These documents were merged into a single standards document in 1995, in the belief that quality care https://doi.org/10.1016/j.transci.2018.04.012 ⁎ Corresponding author. E-mail addresses: mkyuksel@medicine.ankara.edu.tr (M.K. Yüksel), ilhan@medicine.ankara.edu.tr (O. İlhan). Transfusion and Apheresis Science 57 (2018) 153–158 1473-0502/ © 2018 Published by Elsevier Ltd. T